Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty | Zendy

Bengt I. Eriksson | Zendy; Lars C. Borris | Zendy; Richard J. Friedman | Zendy; Sylvia Haas | Zendy; Menno V. Huisman | Zendy; Ajay K. Kakkar | Zendy; Tiemo J. Bandel | Zendy; Horst Beckmann | Zendy; Eva Muehlhofer | Zendy; Frank Misselwitz | Zendy; William Geerts | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty

Author(s) -

Bengt I. Eriksson,

Lars C. Borris,

Richard J. Friedman,

Sylvia Haas,

Menno V. Huisman,

Ajay K. Kakkar,

Tiemo J. Bandel,

Horst Beckmann,

Eva Muehlhofer,

Frank Misselwitz,

William Geerts

Publication year - 2008

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa0800374

Subject(s) - medicine , rivaroxaban , pulmonary embolism , deep vein , surgery , venography , enoxaparin sodium , thrombosis , venous thrombosis , placebo , anesthesia , low molecular weight heparin , warfarin , atrial fibrillation , alternative medicine , pathology

This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those of enoxaparin for extended thromboprophylaxis in patients undergoing total hip arthroplasty.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research